Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | PRCT | IRMD |
|---|---|---|
| Price | $17.91 | $85.47 |
| Change today | ▲ 2.28% | ▲ 0.77% |
| Market cap | $1.03B | $1.09B |
| Return, 3 months | -9.3% | -12.6% |
| Return, year to date | -43.1% | -11.6% |
| Return, 1 year | -48.5% | +12.7% |
| P/E (TTM) | -9.2 | 47.7 |
| P/B | 3.0 | 10.7 |
| P/E percentile vs own 5y | 91st | 72nd |
| Dividend yield | – | 0.87% |
| Revenue growth (YoY, latest qtr) | +19.3% | +0.3% |
| Net profit growth (YoY) | -37.2% | -9.6% |
| Gross margin | 64.2% | 75.9% |
| Operating margin | -33.9% | 31.9% |
| Net margin | -32.5% | 26.7% |
| Return on equity | -30.2% | 23.5% |
| Analyst target vs. price | +29.8% | +40.4% |
| Analyst buy share | 36% | 50% |
| RSI (14) | 43 | 49 |
| 30-day volatility | 55.8% | 22.0% |
| Max drawdown, 1 year | -54.9% | -21.8% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
